UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Modern rheumatology, 2020-01, Vol.30 (1), p.36-43

2020

Volltextzugriff (PDF)

Volenrelaxin (LY3540378) increases Renal Plasma Flow: A Randomized Phase 1 Trial

Nephrology, dialysis, transplantation, 2024-05

2024

Volltextzugriff (PDF)

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

The Lancet. Rheumatology, 2020-06, Vol.2 (6), p.e347-e357

2020

Volltextzugriff (PDF)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib

Rheumatic & musculoskeletal diseases open, 2020-10, Vol.6 (3), p.e001370

2020

Volltextzugriff (PDF)

P644: IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B‐CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS

HemaSphere, 2023-08, Vol.7 (S3), p.e4171997-n/a

2023

Volltextzugriff (PDF)

P621: REAL‐WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT

HemaSphere, 2023-08, Vol.7 (S3), p.e24922b0-n/a

2023

Volltextzugriff (PDF)

Warfarin-induced calciphylaxis: a case report and review of literature

International journal of general medicine, 2013-01, Vol.6 (default), p.665-669

2013

Volltextzugriff (PDF)

Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias

International journal of general medicine, 2013-01, Vol.6 (default), p.515-518

2013

Volltextzugriff (PDF)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1042-1055

2019

Volltextzugriff (PDF)

Hemidiaphragm paresis and granulomatous pneumonitis associated with adalimumab: A case report

Heart & lung, 2014, Vol.43 (1), p.84-86

2014

Volltextzugriff (PDF)

Variability in response to hepatitis B vaccine in hemodialysis patients

Journal of clinical medicine research, 2015-05, Vol.7 (5), p.315-318

2015

Volltextzugriff (PDF)

Methadone Induced Sensorineural Hearing Loss

Case Reports in Medicine, 2013-01, Vol.2013 (2013), p.170-174-044

2013

Volltextzugriff (PDF)

Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7538-7538

2023

Volltextzugriff (PDF)

CLL-402 Real-World Clinical Outcomes of First-Line (1L) Ibrutinib Dose Reduction Versus Acalabrutinib Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S352-S352

2024

Volltextzugriff (PDF)

Alport's Syndrome in Pregnancy

Case Reports in Medicine, 2013-01, Vol.2013 (2013), p.375-377-094

2013

Volltextzugriff (PDF)

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

Annals of the rheumatic diseases, 2018-07, Vol.77 (7), p.988-995

2018

Volltextzugriff (PDF)

CLL-403 Real-World Dosing Patterns and Time to Next Treatment for Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With or Without Ibrutinib Dose Reduction Following an Adverse Event

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S327-S327

2023

Volltextzugriff (PDF)

POSTER: CLL-403 Real-World Dosing Patterns and Time to Next Treatment for Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With or Without Ibrutinib Dose Reduction Following an Adverse Event

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S172-S172

2023

Volltextzugriff (PDF)

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Leukemia & lymphoma, 2024-10, p.1-10

2024

Volltextzugriff (PDF)

Thrombotic Thrombocytopenic Purpura

Journal of blood disorders & transfusion, 2013

Saifan, Chadi

2013

Volltextzugriff (PDF)

Hemidiaphragm Paresis and Granulomatous Pneumonitis Associated With Adalimumab

Chest, 2013, Vol.144 (4), p.674A-674B

2013

Volltextzugriff (PDF)

An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection

The Journal of infectious diseases, 2012-11, Vol.206 (9), p.1367-1371

2012

Volltextzugriff (PDF)

Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study

Vascular health and risk management, 2013-01, Vol.9 (default), p.361-364

2013

Volltextzugriff (PDF)

Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD

International journal of nephrology and renovascular disease, 2016-01, Vol.9 (Issue 1), p.5-10

2016

Volltextzugriff (PDF)

Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements

International journal of nephrology and renovascular disease, 2013, Vol.6 (default), p.89-93

2013

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Original Research
(7)
Complications And Side Effects
(6)
Care And Treatment
(5)
Hemodialysis
(5)
Humans
(5)
Male
(5)
Middle Aged
(5)
Rheumatoid Arthritis
(5)
Rheumatology
(5)
Diagnosis
(4)
Female
(4)
General & Internal Medicine
(4)
Health Aspects
(4)
Medicine, General & Internal
(4)
Risk Factors
(4)
Urology & Nephrology
(4)
Aged
(3)
Arthritis, Rheumatoid - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Volenrelaxin (LY3540378) increases Renal Plasma Flow: A Randomized Phase 1 Trial

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib

P644: IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B‐CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS

P621: REAL‐WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT

Warfarin-induced calciphylaxis: a case report and review of literature

Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Hemidiaphragm paresis and granulomatous pneumonitis associated with adalimumab: A case report

Variability in response to hepatitis B vaccine in hemodialysis patients

Methadone Induced Sensorineural Hearing Loss

Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials

CLL-402 Real-World Clinical Outcomes of First-Line (1L) Ibrutinib Dose Reduction Versus Acalabrutinib Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Alport's Syndrome in Pregnancy

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

CLL-403 Real-World Dosing Patterns and Time to Next Treatment for Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With or Without Ibrutinib Dose Reduction Following an Adverse Event

POSTER: CLL-403 Real-World Dosing Patterns and Time to Next Treatment for Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With or Without Ibrutinib Dose Reduction Following an Adverse Event

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Thrombotic Thrombocytopenic Purpura

Hemidiaphragm Paresis and Granulomatous Pneumonitis Associated With Adalimumab

An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection

Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study

Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD

Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements

Suchergebnisse filtern